PR Newswire·Nov 12, 2026, 10:11 AM ET

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 16, 2026 in Ardelyx, Inc. Lawsuit - ARDX

Ardelyx Chief Commercial Officer Eric Foster is named as an individual defendant in a securities class action alleging he assured investors that the company's patient-access strategy was effective.
The lawsuit claims Foster misled shareholders about payer prior authorization & step edit restrictions that allegedly hindered prescriptions for IBSRELA & XPHOZAH.
The class period covers shares purchased between January 13, 2025, & August 6, 2026.
Ardelyx stock dropped approximately 18% to $4.00 per share on August 7, 2026, following a reduction in IBSRELA revenue guidance & withdrawal of long-term XPHOZAH guidance.
Foster is accused of overseeing commercial strategies & field access teams while allegedly omitting information regarding stricter payer utilization-management processes.
The complaint cites a February 2025 directive to physicians to prescribe based on patient need while Ardelyx adjudicated access, alongside claims that approval rates were "very high."
The lead plaintiff appointment deadline is November 16, 2026.
Claims are filed under Section 10(b) & Rule 10b-5, with a Section 20(a) count seeking to hold Foster accountable as a controlling person.
Investors may qualify for recovery if they purchased shares during the class period & suffered losses, regardless of whether they still hold the stock.
Legal representation is provided by Levi & Korsinsky LLP, with no upfront costs required to evaluate potential recovery.